BDKRB2 and early-onset autosomal dominant Alzheimer disease: To evaluate the effect of the biostable B2R-selective agonist NG291 and the B2R antagonist bradyzide (BDZ) on Alzheimer’s disease development, 12 month-old C57Bl/6 non-transgenic littermate and B6.Cg-Tg (PDGFB-APPSwInd) transgenic mice (WT and TG, respectively) were treated for 60 days (subcutaneous infusion).